This appointment adds a scientific and medical expert to the board but carries no immediate trading signal. Monitor for any strategic shifts in R&D direction or upcoming pipeline catalysts.
BMRN drugs
BMRN drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 14 $66.41entry
- T+1 · 2mo ago −2.95%α −2.49% · $64.45
- T+5 · 8w ago −3.54%α −3.65% · $64.06
- T+20 · 5w ago −16.59%α −18.86% · $55.39
- T+45 · todayOpen
- T+60 · in 21d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
BioMarin appointed Robert Plenge, M.D., Ph.D., to its Board of Directors, expanding the board from ten to eleven members, and granted him $400,000 in restricted stock units. This is a routine director appointment with no material financial implications for the company.
Key Facts
- Board size increased from ten to eleven members with the appointment of Robert Plenge, M.D., Ph.D., effective September 10, 2026.
- Dr. Plenge was appointed to the Science and Technology Committee.
- He received a restricted stock unit grant valued at $400,000, vesting on the date prior to the next annual meeting.
- No departure of existing directors or C-suite executives is reported.
- Dr. Plenge was not selected pursuant to any arrangement with any person and has no reportable related-party transactions.
Financial Impact
Director appointment with a $400,000 RSU grant, immaterial relative to BioMarin's $12.7B market cap.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-061717 |
| Document: 0001628280-26-061717-index-headers.html | 0001628280-26-061717 |
| Document: 0001628280-26-061717-index.html | 0001628280-26-061717 |
| Document: 0001628280-26-061717.txt | 0001628280-26-061717 |
Track record
16 reports on BMRN
2 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +8.91% at T+60 after the Apr 27, 2026 report. 3 of 5 went positive at some point.
Filters
- Nov 4, 202612d ago SC 13G/A Neutral 3/10 Entry $56.12 to $56.70 Now $57.99 +3.33% ▲ +1.03% −2.26% vs SPY
- Nov 2, 202614d ago 8-K Bearish 6/10 Entry $55.66 to $57.13 Now $57.99 −4.19% ▼ −2.64% −3.23% vs SPY
- Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $57.49 to $56.12 Now $57.99 +0.87% ▼ −2.38% +2.34% vs SPY
- Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $56.00 to $57.13 Now $57.99 +3.55% ▲ +2.02% +2.73% vs SPY
- Oct 6, 20265w ago 8-K Bearish 6/10 Entry $55.20 to $55.14 Now $57.99 −5.05% ▲ +0.11% −0.87% vs SPY
- Sep 15, 20268w ago 8-K Neutral 4/10 Entry $64.45 to $63.94 Now $57.99 −10.02% ▼ −0.79% −1.61% vs SPY
- Sep 14, 20269w ago 8-K Neutral 2/10 Viewing Entry $66.41 to $64.06 Now $57.99 −12.68% ▼ −3.54% −3.65% vs SPY
- Sep 1, 202610w ago 8-K Neutral 3/10 Entry $64.84 to $64.41 Now $57.99 −10.56% ▼ −0.66% −0.74% vs SPY
- Sep 1, 202610w ago Press Release Neutral 4/10 Entry $64.84 to $64.41 Now $57.99 −10.56% ▼ −0.66% −0.74% vs SPY
- Aug 31, 202611w ago 8-K Bullish 6/10 Entry $65.23 to $64.63 Now $57.99 −11.10% ▼ −0.92% −0.78% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers